Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 3/20 | 0.44 |
| ▸ | CTSG | P08311 | 2/20 | 0.44 |
| ▸ | TYR | P14679 | 2/20 | 0.40 |
| ▸ | IAPP | P10997 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5590177 | 0.83 | PRKCI (0.57) | PRKCIELANECTSGTYRIAPP | |
| SCHEMBL27454188 | 0.77 | PRKCI (0.44) | PRKCIELANECTSGTYRHMGCR | |
| SCHEMBL16527925 | 0.76 | PRKCI (0.52) | PRKCIELANECTSGTYRIAPP | |
| SCHEMBL5196215 | 0.76 | PRKCI (0.57) | PRKCIELANECTSGTYRIAPP | |
| SCHEMBL9505579 | 0.76 | GABRA1 (0.54) | PRKCIGABRA1GABRB2 | |
| SCHEMBL10438966 | 0.76 | IAPP (0.44) | PRKCIELANECTSGIAPPGABRA1 | |
| SCHEMBL2034606 | 0.75 | TYR (0.52) | PRKCIELANECTSGTYRIAPP | |
| SCHEMBL23387422 | 0.74 | TYR (0.55) | PRKCIELANECTSGTYRIAPP | |
| SCHEMBL5445936 | 0.74 | PRKCI (0.60) | PRKCIELANECTSGTYRIAPP | |
| SCHEMBL28762559 | 0.74 | PRKCI (0.50) | PRKCIELANECTSGTYRIAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957241-B2 | Aromatic diamine, an intermediate therefor, a method for producing the aromatic diamine, and a method for producing the intermediate therefor | SEIKA CORPORATION (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20180079732-A1 | AROMATIC DIAMINE, AN INTERMEDIATE THEREFOR, A METHOD FOR PRODUCING THE AROMATIC DIAMINE, AND A METHOD FOR PRODUCING THE INTERMEDIATE THEREFOR | SEIKA CORPORATION (JP) | 2018-03-22 | — | — | US | disclosed |
| CN-107531652-A | Aromatic diamine, intermediate thereof, and processes for producing these | 精化株式会社 | 2018-01-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079732-A1 | AROMATIC DIAMINE, AN INTERMEDIATE THEREFOR, A METHOD FOR PRODUCING THE AROMATIC DIAMINE, AND A METHOD FOR PRODUCING THE INTERMEDIATE THEREFOR | WEE1, WEE2, WASF2 | PRKCI 4282/4885ELANE 4777/4885CTSG 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.